FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD
A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.
You may also be interested in...
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
US Sen. Bill Cassidy says he wants more details about the FDA’s plans to regulate AI/ML medical software, including a time frame for publishing guidance documents.
Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.